Trial: 202204091

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Phase

II/III

Principal Investigator

Waqar, Saiama

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov